Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients

作者: F. Pacini , L. Agate , R. Elisei , M. Capezzone , C. Ceccarelli

DOI: 10.1210/JCEM.86.9.7831

关键词:

摘要: Detectable serum Tg levels associated with negative diagnostic (131)I whole body scan are not infrequently found in patients differentiated thyroid cancer. Several researchers have shown that these the administration of high activity (100 mCi or more) increases sensitivity a posttherapy performed few days later and allows detection neoplastic foci seen doses (131)I. Empirical radioiodine treatment has also been advocated by some researchers, but its therapeutic effect is controversial. In our institute, positive Tg/negative were treated activities before 1984; afterward, almost all radioiodine, was performed. present retrospective study we compared outcome two groups patients, 42 28 untreated, followed for mean periods 6.7 +/- 3.8 11.9 4.4 yr, respectively. group first 12 30 patients. further administered only latter group. At end follow-up complete remission (normalization off L-thyroxine scan) observed 10 (33.3%). 9 cases (30%) became negative, reduced still detectable; 11 (36.6%) detectable, positive. The resolution uptake lung metastases 8 (88.8%) cervical node 18 (61.1%). once because (n = 12), 2 (16.7%) apparent remission, 7 (58.3%) had detectable values without evidence disease, showed lymph mediastinum, 1 patient (8.3%) died metastases. Of untreated none radiological therapy undetectable 19 (67.9%), significantly 6 (21.4%), unchanged increased 3 (10.7%), whom developed 14 yr after diagnosis. summary, results indicate scan, may utility and, to lesser extent, those However, view frequent normalization believe should be considered according result scan. If lung, continued up total remission; surgical preferred metastases, no used bed uptake.

参考文章(24)
Martin Schlumberger, Maurice Tubiana, Olivier Arcangioli, Claude Parmentier, Jean Daniel Piekarski, Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. The Journal of Nuclear Medicine. ,vol. 29, pp. 1790- 1794 ,(1988)
Geoffrey Coates, Douglas J. Moote, Simon J. Raphael, Albert A. Driedger, Naheel S. Alnafisi, FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. The Journal of Nuclear Medicine. ,vol. 41, pp. 1010- 1015 ,(2000)
J D Pineda, T Lee, K Ain, J C Reynolds, J Robbins, Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. The Journal of Clinical Endocrinology & Metabolism. ,vol. 80, pp. 1488- 1492 ,(1995) , 10.1210/JCEM.80.5.7744991
Shigenobu Nagataki, Kanji Torizuka, THE THYROID 1988 ,(1988)
Ewald Kresnik, Iris Gomez, Peter Lind, Hans J. Gallowitsch, Peter Mikosch, Werner Langsteger, Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. The Journal of Nuclear Medicine. ,vol. 38, pp. 348- 352 ,(1997)
Leonard Wartofsky, Martin Schlumberger, Steven I. Sherman, Ian D. Hay, Jayashree Gopal, THERAPEUTIC CONTROVERSY The Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer ,(1998)
TNM classification of malignant tumours Published in <b>2010</b> in Chichester, West Sussex, UK ;Hoboken, NJ by Wiley-Blackwell. ,(1987) , 10.1007/978-3-642-82982-6
Rossella Elisei, Aldo Pinchera, Francesco Lippi, Stefano Anelli, Claudia Ceccarelli, Furio Pacini, Nunzio Formica, Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. The Journal of Nuclear Medicine. ,vol. 28, pp. 1888- 1891 ,(1987)
F. Pacini, A. Pinchera, C. Giani, L. Grasso, F. Doveri, L. Baschieri, Serum thyroglobulin in thyroid carcinoma and other thyroid disorders Journal of Endocrinological Investigation. ,vol. 3, pp. 283- 292 ,(1980) , 10.1007/BF03348277